Partnership
ULA x Blue Origin (BE-4 Engine)
ULA and Blue Origin established a long-term partnership to jointly fund development of the BE-4 rocket engine for ULA's Vulcan Centaur launch vehicle. Blue Origin has since delivered flight engines to ULA, with the BE-4 powering the Vulcan rocket.
development · Active · operating
Machine-readable surfaces
- Markdown mirror: /partnerships/ula-x-blue-origin-be-4-engine.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/partnerships/ula-x-blue-origin-be-4-engine
- Revision history: /partnerships/ula-x-blue-origin-be-4-engine/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
f8a766c4-5c32-4734-a9a2-8cb5f8184130- Type
- development
- Status
- Activeoperating
- Announced
- 2014-09-1712 years ago
- Active for
- 12 years
Who’s involved
United Launch Alliance (ULA) is a joint venture between [Lockheed Martin](/companies/lockheed-martin) and [Boeing](/companies/boeing) providing space launch services for U.S. national security, [NASA](/companies/nasa), and commercial customers. Founded in December 2006 and headquartered in Centennial, Colorado, ULA operates the Vulcan Centaur rocket — powered by [Blue Origin](/companies/blue-origin) BE-4 engines — and the retiring Atlas V. With ~2,700 employees and ~$1.3B annual revenue, ULA is a primary launch provider for the U.S. Space Force and NRO.
Off-registry parties
- Blue Origin · manufacturer
Related partnerships
Recent partnerships of the same kind
- Canvas x USG CorporationCanvas + USG Corporationdevelopment—operating
- Entegris x SEMATECHEntegris + SEMATECHdevelopment—operating
- Threod Systems x First ShieldFirst Shield + Threod Systemsdevelopment—operating
- RIKEN BDR x Otsuka Pharmaceutical CollaborationRIKEN Center for Biosystems Dynamics + Otsuka Pharmaceuticaldevelopment—operating
- Kautex Textron RESiLiTE Horizon EuropeKautex Textron + Horizon Europe EU Programmedevelopment—operating
- development—operating
Sources (1)
Deploy Watch
Track this partnership.
We notify you when the status changes against primary-source evidence, expansion is verified, or the partnership is terminated.